Alexander Mark Schobel - 09 Aug 2023 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief Innovation/Tech Officer
Issuer ticker: AQST
Reported as of: 09 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Aug 2023, 16:30:22 UTC
Prior SEC filing: 05 May 2023
Next SEC filing: 11 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Alexander Mark Schobel filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 09 Aug 2023.

Key facts

This page summarizes Alexander Mark Schobel's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Aug 2023, 16:30.

Change

Previous filing in this sequence was filed on 05 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 09 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.